{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:33:43Z","timestamp":1786991623178,"version":"build-2736575974"},"reference-count":17,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["HERGEN22D0"],"award-info":[{"award-number":["HERGEN22D0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["RAMOS17A0"],"award-info":[{"award-number":["RAMOS17A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["SINGH19R0"],"award-info":[{"award-number":["SINGH19R0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK089507"],"award-info":[{"award-number":["DK089507"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jcf.2023.08.002","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T15:55:40Z","timestamp":1691510140000},"page":"1048-1053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["The impact of elexacaftor\/tezacaftor\/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1793-2173","authenticated-orcid":false,"given":"Georgene E","family":"Hergenroeder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9427-9548","authenticated-orcid":false,"given":"Anna","family":"Faino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gracia","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D","family":"Cogen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8611-7960","authenticated-orcid":false,"given":"David P","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2309-368X","authenticated-orcid":false,"given":"Kathleen J","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.jcf.2023.08.002_bib0001","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jcf.2023.08.002_bib0002","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jcf.2023.08.002_bib0003","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Resp Crit Care Med"},{"key":"10.1016\/j.jcf.2023.08.002_bib0004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI","author":"Schwarzenberg","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2023.08.002_bib0005","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ccm.2022.06.012","article-title":"Updates in Nutrition Management of Cystic Fibrosis in the Highly Effective Modulator Era","volume":"43","author":"Wilson","year":"2022","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.jcf.2023.08.002_bib0006","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3390\/antiox10030483","article-title":"CFTR Modulator Therapy with Lumacaftor\/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis","volume":"10","author":"Sommerburg","year":"2021","journal-title":"Antioxidants"},{"issue":"2","key":"10.1016\/j.jcf.2023.08.002_bib0007","article-title":"Nutritional Status and Circulating Levels of Fat-Soluble Vitamins in Cystic Fibrosis Patients: A Cohort Study and Evaluation of the Effect of CFTR Modulators","volume":"10","author":"Francalanci","year":"2023","journal-title":"Children (Basel)"},{"key":"10.1016\/j.jcf.2023.08.002_bib0008","first-page":"1","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on vitamin D absorption in cystic fibrosis patients","author":"Wright","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2023.08.002_bib0009","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jcf.2020.06.015","article-title":"Lumacaftor\/ivacaftor improves liver cholesterol metabolism but does not influence hypocholesterolemia in patients with cystic fibrosis","volume":"20","author":"Gelzo","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.08.002_bib0010","article-title":"Papilledema and hypervitaminosis A after elexacaftor\/tezacaftor\/ivacaftor for cystic fibrosis","author":"Miller","year":"2021","journal-title":"Can J Ophthal"},{"issue":"3","key":"10.1016\/j.jcf.2023.08.002_bib0011","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/j.jcf.2022.01.010","article-title":"Hypervitaminosis A with fulminant secondary intracranial hypertension following personalized medicine-based Elexacaftor\/Tezacaftor\/Ivacaftor initiation in a preadolescent with cystic fibrosis","volume":"21","author":"Wisniewski","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.08.002_bib0012","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","author":"Mayer-Hamblett","year":"2022","journal-title":"Lancet Resp Med"},{"issue":"5","key":"10.1016\/j.jcf.2023.08.002_bib0013","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ncp.10899","article-title":"Update on the management of vitamins and minerals in cystic fibrosis","volume":"37","author":"Sankararaman","year":"2022","journal-title":"Nutr Clin Pract"},{"issue":"5","key":"10.1016\/j.jcf.2023.08.002_bib0014","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/TP.0b013e31822790e3","article-title":"Increased Serum Vitamin A and E Levels After Lung Transplantation","volume":"92","author":"Ho","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.jcf.2023.08.002_bib0015","doi-asserted-by":"crossref","unstructured":"Rosenfeld M., Wainwright C.E., Higgins M., et\u00a0al. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. The lancet respiratory medicine. 2018;6(7):545\u2013553. doi:10.1016\/S2213-2600(18)30202-9.","DOI":"10.1016\/S2213-2600(18)30202-9"},{"issue":"6","key":"10.1016\/j.jcf.2023.08.002_bib0016","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jcf.2019.03.009","article-title":"An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2\u20135\u00a0years (KLIMB)","volume":"18","author":"Rosenfeld","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.08.002_bib0017","doi-asserted-by":"crossref","unstructured":"Davies J.C., Wainwright C.E., Sawicki G.S., et\u00a0al. Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. American journal of respiratory and critical care medicine. 2021;203(5):585\u2013593. doi:10.1164\/rccm.202008-3177OC.","DOI":"10.1164\/rccm.202008-3177OC"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932300869X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932300869X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:08:47Z","timestamp":1762031327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919932300869X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S156919932300869X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.08.002","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of elexacaftor\/tezacaftor\/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}